Zealand Pharma A/S (OTCMKTS:ZLDPF) Raised to "Hold" at William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was upgraded by William Blair to a "hold" rating in a research note issued on Thursday,Zacks.com reports.

Several other analysts have also recently issued reports on ZLDPF. JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They set an "overweight" rating on the stock. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, January 21st.

Zealand Pharma A/S Trading Down 5.4 %

Shares of ZLDPF stock traded down $4.52 during trading hours on Thursday, hitting $79.38. The company had a trading volume of 1,552 shares, compared to its average volume of 771. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The stock has a market capitalization of $5.64 billion, a PE ratio of -33.64 and a beta of 0.88. The company's fifty day moving average is $100.26 and its 200 day moving average is $111.51. Zealand Pharma A/S has a fifty-two week low of $78.50 and a fifty-two week high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.19. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The business had revenue of $1.30 million during the quarter, compared to analysts' expectations of $28.11 million. Research analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Remove Ads

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.